International Concurrent Workshop Clinical 9

RA strategy
Day 2  April 22, 16:15 - 17:15  Room 4

Chair:  Hiroko Kobayashi
Department of Gastroenterology and Rheumatology, Fukushima Medical University School of Medicine, Japan

ICW-C9-1  Sero-positivity for rheumatoid factor is an independent predictor for achievement of good EULAR response at 24 weeks in ACPA highpositive RA patients treated with abatacept: Results from Japanese multicenter registry
Nobunori Takahashi
Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan

ICW-C9-2  Early improvement of musculoskeletal ultrasound findings can predict future clinical response to certolizumab pegol in patients with rheumatoid arthritis
Takanori Fujimura
The Center for Rheumatic Diseases, Nara Medical University, Kashihara, Japan

ICW-C9-3  Attaining comprehensive disease remission (CDR) in the first treatment year is most important for predict of sustaining CDR in a long term in rheumatoid arthritis treatment
Ichiro Yoshii
Department of Orthopedic Surgery and Rheumatology, Yoshii Hospital, Japan

ICW-C9-4  Reducing and spacing after achieving sustained remission in rheumatoid patients in real world from local biologics registry
Yuya Takakubo
Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine, Japan

ICW-C9-5  Prospective Study about 6-week Extended Dosing Interval with Tocilizumab Therapy in Rheumatoid Arthritis Patients in Remission Maintenance
Jun Kikuchi
Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Japan

ICW-C9-6  Discontinuation of tofacitinib after achieving low disease activity (LDA) in patients with established rheumatoid arthritis (RA) : A prospective, multicenter, observational study
Satoshi Kubo
The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan